Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Friday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 2.3 %

NYSE:BTX opened at $0.52 on Friday. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The firm has a market cap of $30.59 million, a PE ratio of -0.23 and a beta of 4.61. The stock has a fifty day moving average price of $1.03 and a 200 day moving average price of $1.57.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.